HU210323B - Process for producing growth hormone crystals - Google Patents
Process for producing growth hormone crystals Download PDFInfo
- Publication number
- HU210323B HU210323B HU9300067A HU6793A HU210323B HU 210323 B HU210323 B HU 210323B HU 9300067 A HU9300067 A HU 9300067A HU 6793 A HU6793 A HU 6793A HU 210323 B HU210323 B HU 210323B
- Authority
- HU
- Hungary
- Prior art keywords
- crystals
- hgh
- process according
- growth hormone
- organic solvent
- Prior art date
Links
- 239000013078 crystal Substances 0.000 title claims description 71
- 238000000034 method Methods 0.000 title claims description 49
- 239000000122 growth hormone Substances 0.000 title description 51
- 102000018997 Growth Hormone Human genes 0.000 title description 15
- 108010051696 Growth Hormone Proteins 0.000 title description 15
- 108010000521 Human Growth Hormone Proteins 0.000 claims description 52
- 102000002265 Human Growth Hormone Human genes 0.000 claims description 52
- 239000000854 Human Growth Hormone Substances 0.000 claims description 51
- 239000011701 zinc Substances 0.000 claims description 27
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 25
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical group CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 19
- 238000002425 crystallisation Methods 0.000 claims description 13
- 230000008025 crystallization Effects 0.000 claims description 13
- 239000003960 organic solvent Substances 0.000 claims description 13
- 150000001768 cations Chemical class 0.000 claims description 10
- 238000002360 preparation method Methods 0.000 claims description 7
- 150000002500 ions Chemical class 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 claims description 5
- 239000000463 material Substances 0.000 claims description 5
- 239000000872 buffer Substances 0.000 claims description 4
- 239000003791 organic solvent mixture Substances 0.000 claims description 4
- 150000002576 ketones Chemical class 0.000 claims description 2
- 229910052725 zinc Inorganic materials 0.000 claims description 2
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 claims 1
- 239000000203 mixture Substances 0.000 description 26
- 238000009472 formulation Methods 0.000 description 19
- 239000000243 solution Substances 0.000 description 16
- 239000000725 suspension Substances 0.000 description 11
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 239000008194 pharmaceutical composition Substances 0.000 description 8
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 description 6
- 229940006486 zinc cation Drugs 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 5
- 239000012452 mother liquor Substances 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 238000004255 ion exchange chromatography Methods 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 235000019445 benzyl alcohol Nutrition 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 210000002303 tibia Anatomy 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 108010006025 bovine growth hormone Proteins 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 239000011548 crystallization buffer Substances 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 2
- 241000972773 Aulopiformes Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101001075374 Homo sapiens Gamma-glutamyl hydrolase Proteins 0.000 description 1
- 101000664737 Homo sapiens Somatotropin Proteins 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- 108010013127 Met-human growth hormone Proteins 0.000 description 1
- 101000868138 Ovis aries Somatotropin Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000277331 Salmonidae Species 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- ZOIORXHNWRGPMV-UHFFFAOYSA-N acetic acid;zinc Chemical compound [Zn].CC(O)=O.CC(O)=O ZOIORXHNWRGPMV-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 210000004198 anterior pituitary gland Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001767 cationic compounds Chemical class 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 101150055782 gH gene Proteins 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- -1 human Chemical class 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000021332 multicellular organism growth Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- HEGSGKPQLMEBJL-RKQHYHRCSA-N octyl beta-D-glucopyranoside Chemical compound CCCCCCCCO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HEGSGKPQLMEBJL-RKQHYHRCSA-N 0.000 description 1
- 150000002892 organic cations Chemical class 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000007971 pharmaceutical suspension Substances 0.000 description 1
- 210000003635 pituitary gland Anatomy 0.000 description 1
- 229940089531 polyethylene glycol 3500 Drugs 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000013557 residual solvent Substances 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- JBQYATWDVHIOAR-UHFFFAOYSA-N tellanylidenegermanium Chemical compound [Te]=[Ge] JBQYATWDVHIOAR-UHFFFAOYSA-N 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 239000004246 zinc acetate Substances 0.000 description 1
- 239000011592 zinc chloride Substances 0.000 description 1
- 235000005074 zinc chloride Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/61—Growth hormone [GH], i.e. somatotropin
-
- C—CHEMISTRY; METALLURGY
- C30—CRYSTAL GROWTH
- C30B—SINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
- C30B29/00—Single crystals or homogeneous polycrystalline material with defined structure characterised by the material or by their shape
- C30B29/54—Organic compounds
- C30B29/58—Macromolecular compounds
-
- C—CHEMISTRY; METALLURGY
- C30—CRYSTAL GROWTH
- C30B—SINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
- C30B7/00—Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Crystallography & Structural Chemistry (AREA)
- Materials Engineering (AREA)
- Metallurgy (AREA)
- Endocrinology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Crystals, And After-Treatments Of Crystals (AREA)
- Medicinal Preparation (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DK168790A DK168790D0 (OSRAM) | 1990-07-13 | 1990-07-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HU210323B true HU210323B (en) | 1995-03-28 |
Family
ID=8107212
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU9300067A HUT64086A (en) | 1990-07-13 | 1991-07-12 | Process for producing gh-crystals |
| HU9300067A HU210323B (en) | 1990-07-13 | 1991-07-12 | Process for producing growth hormone crystals |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU9300067A HUT64086A (en) | 1990-07-13 | 1991-07-12 | Process for producing gh-crystals |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US6117984A (OSRAM) |
| EP (1) | EP0540582B1 (OSRAM) |
| JP (1) | JP2524446B2 (OSRAM) |
| AT (1) | ATE110745T1 (OSRAM) |
| AU (1) | AU666465B2 (OSRAM) |
| BG (1) | BG61267B1 (OSRAM) |
| CA (1) | CA2086087C (OSRAM) |
| DE (1) | DE69103755T2 (OSRAM) |
| DK (2) | DK168790D0 (OSRAM) |
| ES (1) | ES2060399T3 (OSRAM) |
| HU (2) | HUT64086A (OSRAM) |
| IE (1) | IE67054B1 (OSRAM) |
| NZ (1) | NZ238904A (OSRAM) |
| PT (1) | PT98297B (OSRAM) |
| RU (1) | RU2108341C1 (OSRAM) |
| WO (1) | WO1992000998A1 (OSRAM) |
| ZA (1) | ZA915446B (OSRAM) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK168790D0 (OSRAM) * | 1990-07-13 | 1990-07-13 | Novo Nordisk As | |
| US6894023B1 (en) * | 1990-07-13 | 2005-05-17 | Novo Nordisk A/S | Growth hormone crystals and a process for production of these GH-crystals |
| HUT69402A (en) * | 1991-12-20 | 1995-09-28 | Novo Nordisk As | Process for producing stabilized pharmaceutical formulations comprising growth hormone and histidine |
| SE9302278D0 (sv) * | 1992-10-28 | 1993-07-02 | Kabi Pharmacia Ab | Growth hormone |
| KR20000057693A (ko) | 1996-12-20 | 2000-09-25 | 다케다 야쿠힌 고교 가부시키가이샤 | 지효성 제제의 제조 방법 |
| US6541606B2 (en) | 1997-12-31 | 2003-04-01 | Altus Biologics Inc. | Stabilized protein crystals formulations containing them and methods of making them |
| JP3723857B2 (ja) * | 1998-02-04 | 2005-12-07 | 日本ケミカルリサーチ株式会社 | ヒト成長ホルモン含有水性医薬組成物 |
| US7101575B2 (en) | 1998-03-19 | 2006-09-05 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. | Production of nanocapsules and microcapsules by layer-wise polyelectrolyte self-assembly |
| US6451347B1 (en) | 1999-03-01 | 2002-09-17 | Alkermes Controlled Therapeutics, Inc. | Method for purifying human growth hormone |
| ATE226267T1 (de) * | 1999-06-10 | 2002-11-15 | Max Planck Gesellschaft | Einkapselung von kristallen mit mehrschichtigem überzug |
| US6566329B1 (en) | 1999-06-28 | 2003-05-20 | Novo Nordisk A/S | Freeze-dried preparation of human growth hormone |
| TWI283182B (en) | 2000-08-07 | 2007-07-01 | Nektar Therapeutics | Inhalable spray dried 4-helix bundle protein powders having minimized aggregation |
| ATE409465T1 (de) | 2000-10-06 | 2008-10-15 | Pacira Pharmaceuticals Inc | Parenteral verabreichbare mikropartikel- zubereitung mit kontrollierter freisetzung |
| SE517422C2 (sv) | 2000-10-06 | 2002-06-04 | Bioglan Ab | Farmaceutiskt acceptabel stärkelse |
| SE517421C2 (sv) | 2000-10-06 | 2002-06-04 | Bioglan Ab | Mikropartiklar, lämpade för parenteral administration, väsentligen bestående av stärkelse med minst 85 % amylopektin och med reducerad molekylvikt, samt framställning därav |
| SE518007C2 (sv) | 2000-11-16 | 2002-08-13 | Bioglan Ab | Förfarande för framställning av mikropartiklar |
| US7105181B2 (en) | 2001-10-05 | 2006-09-12 | Jagotec, Ag | Microparticles |
| SE0201599D0 (sv) | 2002-03-21 | 2002-05-30 | Skyepharma Ab | Microparticles |
| SE0202719D0 (sv) * | 2002-09-13 | 2002-09-13 | Pharmacia Ab | Process for mfg crystals of growth hormone |
| SG176314A1 (en) | 2002-12-31 | 2011-12-29 | Altus Pharmaceuticals Inc | Human growth hormone crystals and methods for preparing them |
| BR0317896A (pt) * | 2002-12-31 | 2005-12-06 | Altus Pharmaceuticals Inc | Complexos de cristais de proteìna e polìmeros iÈnicos |
| CN1744914A (zh) * | 2002-12-31 | 2006-03-08 | 阿尔特斯制药公司 | 人生长激素晶体和制备它们的方法 |
| WO2005014034A1 (en) * | 2003-07-14 | 2005-02-17 | Nps Allelix Corp. | Stabilized formulation of parathyroid hormone |
| US20090023629A1 (en) * | 2005-12-23 | 2009-01-22 | Altus Pharmaceuticals Inc. | Compositions comprising polycation-complexed protein crystals and methods of treatment using them |
| WO2008076819A2 (en) * | 2006-12-18 | 2008-06-26 | Altus Pharmaceuticals Inc. | Human growth hormone formulations |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA653324A (en) * | 1962-12-04 | G. Brink Norman | Growth hormone and methods of preparing the same | |
| US2143590A (en) * | 1936-09-26 | 1939-01-10 | Univ Alberta | Insulin preparation and process of producing crystals of insulin |
| US2174862A (en) * | 1938-12-30 | 1939-10-03 | Frederick Stearns & Company | Process of producing crystalline insulin |
| US2595278A (en) * | 1950-04-28 | 1952-05-06 | Armour & Co | Preparation of insulin from pancreas glands |
| US3102077A (en) * | 1953-08-19 | 1963-08-27 | Christensen Henry Marinus | Preparation of insulin containing 2.75 to 8 percent zinc content |
| US2897117A (en) * | 1955-02-10 | 1959-07-28 | Univ Alberta | Insulin process |
| US3856771A (en) * | 1973-07-16 | 1974-12-24 | Lilly Co Eli | Process for manufacturing alkali metal or ammonium insulin |
| KR890002631B1 (ko) * | 1984-10-04 | 1989-07-21 | 몬산토 캄파니 | 생물학적으로 활성인 소마토트로핀을 지속적으로 유리하는 조성물 |
| EP0343696B1 (en) * | 1984-10-04 | 1996-01-03 | Monsanto Company | Zinc-associated somatotropins |
| IL79681A (en) * | 1985-08-12 | 1991-06-10 | Int Minerals & Chem Corp | Transition metal complexes of growth hormones and their prolonged release compositions |
| JPS63216898A (ja) * | 1987-01-30 | 1988-09-09 | インターナシヨナル・ミネラルズ・アンド・ケミカル・コーポレイシヨン | 希薄水溶液からソマトトロビンを回収する方法 |
| US4764592A (en) * | 1987-04-23 | 1988-08-16 | Eli Lilly And Company | Crystalline human proinsulin and process for its production |
| ATE198353T1 (de) * | 1988-08-24 | 2001-01-15 | American Cyanamid Co | Stabilisierung von somatotropinen durch modifikation von cystein-resten durch orts- spezifische mutagenese oder chemische derivatisierung |
| US5109117A (en) * | 1990-06-26 | 1992-04-28 | Monsanto Company | Method of somatotropin naturation using urea and a soluble organic alcohol |
| US5780599A (en) * | 1990-07-13 | 1998-07-14 | Novo Nordisk A/S | Growth hormone crystals and a process for production of growth hormone crystals |
| DK168790D0 (OSRAM) * | 1990-07-13 | 1990-07-13 | Novo Nordisk As |
-
1990
- 1990-07-13 DK DK168790A patent/DK168790D0/da active IP Right Grant
-
1991
- 1991-07-10 NZ NZ238904A patent/NZ238904A/xx unknown
- 1991-07-11 PT PT98297A patent/PT98297B/pt not_active IP Right Cessation
- 1991-07-12 DK DK91913240.7T patent/DK0540582T3/da active
- 1991-07-12 CA CA002086087A patent/CA2086087C/en not_active Expired - Fee Related
- 1991-07-12 HU HU9300067A patent/HUT64086A/hu unknown
- 1991-07-12 AT AT91913240T patent/ATE110745T1/de not_active IP Right Cessation
- 1991-07-12 DE DE69103755T patent/DE69103755T2/de not_active Expired - Fee Related
- 1991-07-12 ES ES91913240T patent/ES2060399T3/es not_active Expired - Lifetime
- 1991-07-12 JP JP3512511A patent/JP2524446B2/ja not_active Expired - Fee Related
- 1991-07-12 ZA ZA915446A patent/ZA915446B/xx unknown
- 1991-07-12 WO PCT/DK1991/000203 patent/WO1992000998A1/en not_active Ceased
- 1991-07-12 AU AU82846/91A patent/AU666465B2/en not_active Ceased
- 1991-07-12 HU HU9300067A patent/HU210323B/hu unknown
- 1991-07-12 EP EP91913240A patent/EP0540582B1/en not_active Expired - Lifetime
- 1991-07-12 RU RU93005051/13A patent/RU2108341C1/ru not_active IP Right Cessation
- 1991-07-12 IE IE244491A patent/IE67054B1/en not_active IP Right Cessation
-
1993
- 1993-01-12 BG BG97281A patent/BG61267B1/bg unknown
-
1998
- 1998-04-21 US US09/063,749 patent/US6117984A/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP0540582A1 (en) | 1993-05-12 |
| RU2108341C1 (ru) | 1998-04-10 |
| BG97281A (bg) | 1994-03-24 |
| JP2524446B2 (ja) | 1996-08-14 |
| DK0540582T3 (da) | 1995-01-30 |
| HUT64086A (en) | 1993-11-29 |
| DK168790D0 (OSRAM) | 1990-07-13 |
| IE67054B1 (en) | 1996-02-21 |
| HU9300067D0 (en) | 1993-04-28 |
| DE69103755T2 (de) | 1995-02-23 |
| ATE110745T1 (de) | 1994-09-15 |
| BG61267B1 (en) | 1997-04-30 |
| JPH05507497A (ja) | 1993-10-28 |
| AU666465B2 (en) | 1996-02-15 |
| NZ238904A (en) | 1993-04-28 |
| AU8284691A (en) | 1992-02-04 |
| CA2086087C (en) | 1999-09-14 |
| DE69103755D1 (de) | 1994-10-06 |
| CA2086087A1 (en) | 1992-01-14 |
| ES2060399T3 (es) | 1994-11-16 |
| PT98297A (pt) | 1992-05-29 |
| EP0540582B1 (en) | 1994-08-31 |
| IE912444A1 (en) | 1992-01-15 |
| PT98297B (pt) | 1999-01-29 |
| WO1992000998A1 (en) | 1992-01-23 |
| ZA915446B (en) | 1992-03-25 |
| US6117984A (en) | 2000-09-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HU210323B (en) | Process for producing growth hormone crystals | |
| RU2122426C1 (ru) | Фармацевтический препарат, содержащий гормон роста или производное гормона роста и гистидин или производное гистидина, препарат, представляющий собой кристаллы гормона роста, содержащие гистидин или производное гистидина и способ получения кристаллов гормона роста и гистидина или производного гистидина | |
| DE69631996T2 (de) | Verfahren zur Herstellung von acylierten Proteinpuder | |
| JPH03502794A (ja) | ヒトレラキシン製剤 | |
| CH683749A5 (de) | Pharmazeutische Nasalzusammensetzung. | |
| FR2576792A1 (fr) | Composition pharmaceutique a base d'erythropoietine humaine pour le traitement de l'anemie de l'arthrite rhumatoide | |
| EP0138216A2 (en) | Sustained-release IFN preparation for parenteral administration | |
| US5780599A (en) | Growth hormone crystals and a process for production of growth hormone crystals | |
| JPH04506809A (ja) | 界面活性剤組成物および方法 | |
| DE19716154A1 (de) | Stabile pharmazeutische Darreichungsform für Peptide, Proteine und Nukleinsäuren | |
| JPH08505617A (ja) | インシュリン状成長因子を含有する安定溶液 | |
| US5552161A (en) | Low viscosity, highly concentrated surfactant suspension | |
| JPS6133817B2 (OSRAM) | ||
| MC1099A1 (fr) | Médicament à base d'un polypeptide | |
| US6894023B1 (en) | Growth hormone crystals and a process for production of these GH-crystals | |
| US5922677A (en) | Therapeutic method and compounds of use therein | |
| JP2681467B2 (ja) | ヒト白血球インターフエロン含有局所用組成物 | |
| DE1792196A1 (de) | Verfahren zur Stabilisierung eines Proteins | |
| RU2062619C1 (ru) | Способ получения препарата фолликулостимулирующего гормона из аденогипофизов животных | |
| RU2438680C1 (ru) | Способ получения препарата фолликулостимулирующего гормона из аденогипофизов животных | |
| KR20250121364A (ko) | 결정형, 및 그의 생산을 위한 공정 | |
| CN120168394A (zh) | 一种活性氧响应性雷公藤甲素前药免疫调节水凝胶制剂及其制备方法和应用 | |
| Vann et al. | Activation of an ascorbic acid concentrating mechanism by some corticosteroids in vitro | |
| BRPI0905465B1 (pt) | Processo de extração de hormônios de glândulas de animais, hormônios semipurificados e seu uso em composições farmacêuticas e/ou veterinárias |